Eli Lilly: target ranges raised for 2024

(CercleFinance.com) - On its quarterly publication, Eli Lilly announced that it is raising its annual adjusted EPS target range by $1.
30, to $13.50 to $14, for revenues that are up another $2bn, to between $42.4bn and $43.6bn.

For Q1 2024, the pharmaceutical company posted a 59% increase in adjusted EPS (non-GAAP) to $2.58, including $0.10 in acquired intellectual property charges.

At $8.77bn, sales rose 26% (of which 10% in volume growth and 16% in price increases), driven by its flagship drugs Mounjaro, Zepbound, Verzenio and Jardiance.


Copyright (c) 2024 CercleFinance.com. All rights reserved.